Want to find your lens? Five questions, no jargon — they tell you which of four reads fits how you already think.
Fairly priced — no edge either way.
Close to fair value. Not a bargain, not a rip-off. Come back if the price moves.
The five checks
2 good · 2 caution · 1 warning
- CautionRoughly fairFair value ~$864 sits close to the $955 price — no real margin of safety either way.
- WarningPrice assumes a big accelerationYou'd need ~7%/yr free-cash-flow growth to justify today's price; it has done -2.7%/yr lately.
- GoodRevenue still growingUp 1.0% last year — demand isn't the problem.
- CautionCash flow flat-to-downFree cash flow ~-2.7%/yr — big, but not compounding. The crux for a value buyer.
- GoodFortress balance sheetNet cash positive (+$16B) — little solvency risk.
Price against fair value
What today's price assumes
Hold the price fixed and work backwards: how fast would free cash flow have to grow for $955 to make sense?
Price assumes a big acceleration.
How fair value is calculated
No analyst forecasts, no black box, no AI. Six lines from the filing to the answer.
- Free cash flow, FY25Operating cash flow less capital spending, from the annual report$4.08B
- Ten years of it, growing 5% a year, each counted 9% lessThe same growth and discount for every company$33.41B
- Everything after year tenGrowing 2.5% a year, counted the same way+ $44.27B
- The business, in today's money$77.68B
- Add net cashCash and securities less borrowings and finance leases+ $16.16B
- Divide by the shares on file÷ 0.1086B
Fair value per share$864
If our assumptions are wrong
Fair value per share under a faster or slower decade, and a gentler or harsher discount. The corners are where the $681 to $1,144 range comes from.
| 3% growth | 5% growth | 7% growth | |
|---|---|---|---|
| 8% discount | $877 | $1,000 | $1,144 |
| 9% discount | $764 | $864 | $981 |
| 10% discount | $681 | $765 | $862 |
The blue cell is the published method. Some cells sit above today’s price, some below.
Free cash flow, ten years
$ billions · Form 10-K
What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.
How this was built. Every figure is computed from Regeneron Pharmaceuticals, Inc.'s SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. Fundamentals are from the FY25 annual report and change only when a new one is filed. Price of $955.47 taken 2026-11-15 (Google Finance, manual entry, 2026-11-13) — it is not live and does not move during the day.
Read Regeneron another way
TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →